Activity Summary:
The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this podcast activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year.

Activity Summary:
The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this Clinical Clip activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year.

Activity Summary:
During this educational podcast, Dr. Sonali Bose highlights the latest advances in COPD presented at the American Thoracic Society (ATS) International Conference in San Francisco, CA, May 17-21, 2025.

Noteworthy presentations, posters, and abstracts are presented from the conference that are of high clinical significance to improve COPD.

Activity Summary:
Chronic Obstructive Pulmonary Disease (COPD) remains a major global health burden with significant gaps in early diagnosis, personalized treatment, exacerbation prevention, and coordinated care. During this Clinical Clip video, Dr. Sonali Bose highlights the latest advances in COPD presented at the American Thoracic Society (ATS) International Conference in San Francisco, CA, May 17-21, 2025.

Activity Summary:
There continues to be significant progress in the treatment of primary biliary cholangitis (PBC) and these Clinical Clips from EASL 2025 have focused on the most impactful data presented at this conference. Dr. Nancy Reau will summarize key advances from EASL 2025 and describe their implications for clinical practice. 

Activity Summary:
There continues to be significant progress in the treatment of primary biliary cholangitis (PBC) and these Clinical Clips from EASL 2025 have focused on the most impactful data presented at this conference. Dr. Nancy Reau will summarize key advances from EASL 2025 and describe their implications for clinical practice. 

Activity Summary:
In this podcast titled "Emerging Evidence in Myasthenia Gravis: Key Updates from AAN 2025," Dr. Nicholas Silvestri provides healthcare professionals with an actionable update on recent advancements in MG; which features insights from groundbreaking research presented at AAN 2025.

Activity Summary:
Myasthenia Gravis (MG) has had significant advances, however critical gaps persist in optimizing care. Challenges include variability in diagnostic accuracy, particularly in seronegative cases, and a limited adoption of newer, more sensitive testing modalities. Additionally, the evolving treatment landscape—with emerging therapies such as complement inhibitors and FcRn antagonists—highlights the need for clinicians to stay informed about the latest evidence and integrate these options into personalized care strategies. Addressing these gaps is crucial to improving patient care, enhancing quality of life, and reducing the burden of long-term side effects associated with traditional treatments.

This special edition podcast series with Dr. Nicholas Silvestri enables healthcare providers to engage with evidence-based insights and practical guidance on MG management at their convenience. The podcast format is ideal for professionals to access while commuting, during breaks, or between patient appointments, providing targeted learning without disrupting their workflow.

Activity Summary:
In this Clinical Clip, Dr. Nicholas Silvestri provides a concise and clinically relevant summary of the most important emerging data presented at AAN 2025 that impact the management of generalized Myasthenia Gravis (gMG).

Topics covered include pivotal updates from recent clinical trials—such as MINT (inebilizumab), ADAPT NXT (efgartigimod), and MycarinG (rozanolixizumab)—highlighting the safety, efficacy, and practical implications of emerging therapies across diverse MG subtypes. The activity also explores trends in real-world treatment patterns, therapeutic inertia among neurologists, and new diagnostic approaches including advanced serologic testing and AI-supported electrophysiologic tools. With a focus on individualized care, this activity equips healthcare professionals with key insights to help integrate new therapies and diagnostic innovations into practice, ultimately supporting timely, targeted, and patient-centered management of MG.

Activity Summary:
We are pleased to have recently held the Optimal Management of HIV Disease & Hepatitis: Clinical Conference XXXIII (OPMAN). The conference took place March 22-23, 2025, in Washington, D.C. with leading clinicians and researchers presenting an array of topics covering HIV disease and liver disease. The presentations offered a unique distillation of clinically focused data tailored for practicing HIV and hepatitis healthcare professionals.

These accredited video archives of OPMAN XXXIII provide access to each day of the conference, including clinical presentations, interactive case discussions, and panel discussions addressing audience questions. Continuing education credit is provided for each segment, so you may participate in your area(s) of interest. We hope you enjoy this activity!

Activity Summary:
Managing psoriasis (PsO) and psoriatic arthritis (PsA) presents multiple challenges for healthcare professionals, including staying up to date with emerging therapies, recognizing early signs of PsA, managing comorbidities, and implementing multidisciplinary care strategies. Despite advances in biologic and systemic therapies, unmet needs persist in timely diagnosis, patient education, and comprehensive disease management. Busy healthcare professionals often lack the time for in-depth study of the latest research, creating a critical need for concise, accessible educational opportunities. These unmet needs point to the necessity of practical, time-efficient programs that provide actionable insights into new treatment protocols and improve patient outcomes.

These podcast episodes are designed to provide healthcare professionals with an in-depth exploration of the most recent advances in the management of psoriasis (PsO) and psoriatic arthritis (PsA). The segments will focus on key challenges in clinical practice, including early diagnosis, personalized treatment strategies, and the integration of patient-reported outcomes. It will also address the management of associated comorbidities and the latest therapeutic developments, including biologics and small molecules.

Activity Summary:
Managing psoriasis (PsO) and psoriatic arthritis (PsA) presents multiple challenges for healthcare professionals, including staying up to date with emerging therapies, recognizing early signs of PsA, managing comorbidities, and implementing multidisciplinary care strategies. Despite advances in biologic and systemic therapies, unmet needs persist in timely diagnosis, patient education, and comprehensive disease management. Busy healthcare professionals often lack the time for in-depth study of the latest research, creating a critical need for concise, accessible educational opportunities. These unmet needs point to the necessity of practical, time-efficient programs that provide actionable insights into new treatment protocols and improve patient outcomes.

These Mini-Modules are designed to provide healthcare professionals with an in-depth exploration of the most recent advances in the management of psoriasis (PsO) and psoriatic arthritis (PsA). The segments will focus on key challenges in clinical practice, including early diagnosis, personalized treatment strategies, and the integration of patient-reported outcomes. It will also address the management of associated comorbidities and the latest therapeutic developments, including biologics and small molecules.

Activity Summary:
Adolescents are disproportionately affected by HIV, accounting for approximately 1 in 5 new HIV infections in the United States. The expanded options for pre-exposure prophylaxis (PrEP) in adolescents provides clinicians with additional, effective tools to further reduce the risk of HIV transmission in this group. Once diagnosed, youth with HIV are the least likely out of any age group to be linked to care and achieve viral suppression once on ART.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of "what you need to know" podcast episodes from data presented at CROI 2025.

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Clinical Clips will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of "what you need to know" videos from data presented at CROI 2025.

Activity Summary:
Significant disparities in HIV acquisition risk, access to ART, and viral suppression persist in the United States between racial groups, specific populations, and geographies, among others. Long-acting ART expands existing options for HIV treatment. Further, understanding the appropriate use of ART options along with prevention and management of co-morbidities strategies are critical in the long-term management of HIV.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Pre-exposure prophylaxis (PrEP) provides safe and robust protection again HIV infection in a diversity of populations at risk. In addition, PrEP when used in combination with other approaches has led to reductions in population-level HIV incidence at regional and city levels. This activity will discuss the impact of PrEP on ending the HIV epidemic, benefits and limitations of new and future PrEP options, and strategies to improve sustainable implementation of PrEP.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
The Simply Speaking HIV lecture series includes a curriculum that highlights the very latest clinical data utilizing a PowerPoint slide presentation developed and approved by key expert physicians and further reviewed and approved by the Planning Committee. The slides will be continuously evaluated and updated for current relevance.

Activity Summary:
There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In this podcast series, Dr. Jonathan C. Roberts and Dr. Mindy Simpson inform and guide on safely integrating recently approved agents into the treatment continuum while ensuring alignment with critical new breakthroughs and enabling patient-focused care pathways.

Activity Summary:
There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In these mini-module episodes, Dr. Jonathan C. Roberts and Dr. Mindy Simpson inform and guide on safely integrating recently approved agents into the treatment continuum while ensuring alignment with critical new breakthroughs and enabling patient-focused care pathways.

Activity Summary:

Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune liver disease that can progress to end-stage liver disease. Recent developments have led to important updates in the diagnosis and use of novel approaches in treatment for patients with PBC. This podcast will utilize a case-based discussion to address implications of risk stratification and practice-changing evidence for the long-term management among diverse patients with PBC. 

Activity Summary:
Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune liver disease that can progress to end-stage liver disease. Recent developments have led to important updates in the diagnosis and use of novel approaches in treatment for patients with PBC. This program will utilize case-based discussion to address implications of risk stratification and practice-changing evidence for the long-term management among diverse patients with PBC.

Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.